Johnson & Johnson announced positive topline results from the investigational phase III MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide.
David Mitchell, a tireless patient advocate whose lived experience with multiple myeloma shaped a decade of courageous leadership on behalf of patients nationwide, died Jan. 2. He was 75.
